The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
EV-302: Long-term subgroup analysis from the phase 3 global study of enfortumab vedotin in combination with pembrolizumab (EV+P) vs chemotherapy (chemo) in previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC).
 
Jens Bedke
Consulting or Advisory Role - Apogepha; Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Daiichi Sankyo Europe GmbH; Eisai; Ipsen; Janssen; Merck KGaA; MSD Oncology; Pfizer; Roche
Speakers' Bureau - Apogepha; Astellas Pharma; Bristol-Myers Squibb; Ipsen; Merck KGaA; MSD Oncology; Pfizer
Research Funding - Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); Ipsen (Inst); MSD Oncology (Inst); Pfizer (Inst); Roche (Inst); SeaGen (Inst)
Travel, Accommodations, Expenses - Ipsen (Inst); Merck KGaA (Inst)
 
Thomas Powles
Honoraria - Astellas Pharma; AstraZeneca; BMS GmbH & Co. KG; Eisai; Exelixis; Incyte; Ipsen; Johnson & Johnson/Janssen; MashupMD; Merck; Merck Serono; Novartis; Pfizer; Roche; Seagen
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Eisai; Exelixis; Incyte; Ipsen; Johnson & Johnson; MashupMD; Merck; Merck Serono; MSD; Novartis; Pfizer; Roche; Seagen
Research Funding - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Eisai; Exelixis; Ipsen; Johnson & Johnson; Merck Serono; MSD; Novartis; Pfizer; Roche; Seagen
Travel, Accommodations, Expenses - AstraZeneca; Ipsen; MSD; Pfizer; Roche
 
Begoña Valderrama
Honoraria - AAA HealthCare; Almirall; Astellas Pharma; AstraZeneca Spain; Bayer; Bristol-Myers Squibb/Medarex; Janssen Oncology; Merck; MSD Oncology; Pfizer
Consulting or Advisory Role - Advanced Accelerator Applications/Novartis; Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb/Medarex; Janssen Oncology; Merck; MSD Oncology; Pfizer; Recordati
Travel, Accommodations, Expenses - Astellas Pharma; Bristol-Myers Squibb; Merck; MSD Oncology; Pfizer; Roche
 
Shilpa Gupta
Stock and Other Ownership Interests - BioNTech SE; Moderna Therapeutics; Nektar
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb/Medarex; Foundation Medicine; Genzyme; Gilead Sciences; Merck; Natera; Pfizer; Seagen
Speakers' Bureau - Bristol-Myers Squibb; Gilead Sciences; Seagen
Research Funding - Bristol Myers Squibb Foundation (Inst); EMD Serono (Inst); Exelixis (Inst); Gilead Sciences (Inst); Merck (Inst); Moderna Therapeutics (Inst); Novartis (Inst); QED Therapeutics (Inst); Roche/Genentech (Inst); Seagen (Inst); Tyra Biosciences (Inst)
Patents, Royalties, Other Intellectual Property - UpToDate author royalty
Travel, Accommodations, Expenses - Pfizer
 
Eiji Kikuchi
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Chugai Pharma; Daiichi Sankyo/UCB Japan; Ferring; Janssen; Merck; MSD; Ono Pharmaceutical
Speakers' Bureau - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb-Ono Pharmaceutical; Chugai Pharma; Eisai; Janssen; Kissei Pharmaceutical; Kyorin; Merck; MSD; Nippon Kayaku; Sanofi; Seagen; Taiho Pharmaceutical; Takeda
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb Japan (Inst); Chugai Pharma (Inst); Daiichi Sankyo/UCB Japan (Inst); Janssen (Inst); Kyorin (Inst); Kyowa Kirin International (Inst); Merck (Inst); MSD (Inst); Nihonkayaku (Inst); Nippon Shinyaku (Inst); Otsuka (Inst); Taiho Pharmaceutical (Inst)
 
Yohann Loriot
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Gilead Sciences; Janssen; Loxo/Lilly; Merck KGaA; MSD Oncology; MSD Oncology (Inst); Pfizer (Inst); Pfizer/EMD Serono; Roche; Roche (Inst); Seagen
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); BMS (Inst); Exelixis (Inst); Gilead Sciences (Inst); Incyte (Inst); Janssen Oncology (Inst); Merck KGaA (Inst); MSD Oncology (Inst); Pfizer (Inst); Roche (Inst); Sanofi (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst); Tyra Biosciences (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca; Janssen Oncology; MSD Oncology; Roche; Seagen
 
Matthew Galsky
Consulting or Advisory Role - Abbvie; AstraZeneca; Bicycle Therapeutics; Bristol-Myers Squibb; Curis; Daiichi Sankyo Europe GmbH; EMD Serono; Gilead Sciences; Janssen; Merck; Pfizer; Seagen
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Dendreon (Inst); Genentech/Roche (Inst); Janssen Oncology (Inst); Merck (Inst); Novartis (Inst)
Patents, Royalties, Other Intellectual Property - METHODS AND COMPOSITIONS FOR TREATING CANCER AND RELATED METHODS. MOUNT SINAI SCHOOL OF MEDICINE July 2012 Application number: 20120322792
 
Srikala Sridhar
Consulting or Advisory Role - AstraZeneca (Inst); Bayer (Inst); Bicycle Therapeutics (Inst); Bristol-Myers Squibb (Inst); EMD Serono (Inst); Gilead Sciences (Inst); Janssen (Inst); Merck (Inst); Pfizer (Inst); Seagen (Inst)
Research Funding - Bayer (Inst); Janssen (Inst); Pfizer (Inst)
 
Evan Yu
Consulting or Advisory Role - Advanced Accelerator Applications; Bayer; Bristol Myers Squibb; Janssen; Loxo/Lilly; Merck; Oncternal Therapeutics
Research Funding - Bayer (Inst); Blue Earth Diagnostics (Inst); Dendreon (Inst); Lantheus Medical Imaging (Inst); Merck (Inst); Oncternal Therapeutics (Inst); Seagen (Inst); Tyra Biosciences (Inst)
 
Jeannie Hoffman-Censits
Honoraria - Clovis Oncology; Roche/Genentech; Roche/Genentech; Roche/Genentech; Roche/Genentech; Roche/Genentech
Consulting or Advisory Role - AstraZeneca; Foundation medicine; Gilead Sciences; Roche/Genentech; Seagen
Research Funding - Astellas Pharma (Inst); Daiichi Sankyo (Inst); EMD Serono (Inst); Foundation Medicine; Genentech; Genentech; Sanofi; Seagen (Inst)
Travel, Accommodations, Expenses - Roche/Genentech
 
Gopa Iyer
Consulting or Advisory Role - AstraZeneca; Bicycle Therapeutics; Flare Therapeutics; Janssen; Loxo/Lilly; Mirati Therapeutics
Research Funding - AADi (Inst); Flare Therapeutics (Inst); Janssen (Inst); Loxo/Lilly (Inst); Pfizer (Inst)
 
Daniel Castellano Gauna
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Ipsen; Janssen Oncology; Lilly; MSD Oncology; Novartis; Pfizer; Pierre Fabre; Roche/Genentech; Sanofi
Research Funding - Janssen Oncology (Inst)
Travel, Accommodations, Expenses - AstraZeneca Spain; Bristol-Myers Squibb; Novartis; Pfizer; Roche
 
Pablo Maroto-Rey
Consulting or Advisory Role - Astellas Pharma; Bayer; BMS; Ipsen; Janssen; Merck/Pfizer; MSD
Expert Testimony - Amgen
Travel, Accommodations, Expenses - Bayer; Ipsen; Merck/Pfizer
 
Nataliya Mar
Consulting or Advisory Role - AVEO; EMD Serono; Exelixis; Pfizer
Speakers' Bureau - Eisai; Merck
Research Funding - Gilead Sciences
 
Nancy Dawson
Honoraria - Astellas Pharma; AstraZeneca; Bayer; Eisai; EMD Serono; Exelixis; Janssen Biotech; Lantheus Medical Imaging; Merck; Pfizer; Seagen; Sumitomo Pharma Oncology
Speakers' Bureau - Amgen; Astellas Pharma; AstraZeneca; Eisai; EMD Serono; Exelixis; Genentech/Roche; Janssen Biotech; Merck; Pfizer; Sanofi
Research Funding - Bayer (Inst); Janssen (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Caris Life Sciences
 
Abhishek Bavle
Employment - Merck Sharp & Dohme
Stock and Other Ownership Interests - Merck Sharp & Dohme
 
Seema Gorla
Employment - Astellas Pharma
Research Funding - Astellas Pharma
Travel, Accommodations, Expenses - Astellas Pharma
 
Xuesong Yu
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer
 
Yi-Tsung Lu
Employment - Pfizer; Seagen
Stock and Other Ownership Interests - Pfizer; Seagen
Patents, Royalties, Other Intellectual Property - US Patent No. 10823736 Method of assessing disease condition of cancer
Travel, Accommodations, Expenses - Pfizer; Seagen
 
Michiel Van Der Heijden
Consulting or Advisory Role - Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); Janssen (Inst); MSD Oncology (Inst); Pfizer (Inst); Seagen (Inst)
Research Funding - 4SC (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); MSD Oncology (Inst); Roche (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb (Inst)